Ultragenyx Pharmaceutical Inc. — fact timeline

Ultragenyx Pharmaceutical Inc. shareholders approved Advisory (Non-Binding) Vote to Approve Executive Compensation at the 2026-05-14 meeting.

“Proposal No. 4 – Advisory (Non-Binding) Vote to Approve Executive Compensation At the Annual Meeting, the Company’s stockholders voted, on an advisory basis, in favor of a resolution approving the compensation the Company pays to its “named executive officers” as described in the Proxy Statement. The votes on Proposal 4 were as follows: Votes For Votes Against Abstentions Broker Non-Votes 70,945,277 2,594,517 34,704 11,211,890”

Ultragenyx Pharmaceutical Inc. shareholders approved Ratification of Selection of Independent Registered Accounting Firm at the 2026-05-14 meeting.

“Proposal No. 3 – Ratification of Selection of Independent Registered Accounting Firm At the Annual Meeting, the Company’s stockholders ratified the selection of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2026. The votes on Proposal 3 were as follows: Votes For Votes Against Abstentions 84,551,399 221,802 13,187”

Ultragenyx Pharmaceutical Inc. shareholders approved Approval of the Third A&R 2023 Plan at the 2026-05-14 meeting.

“Proposal No. 2 – Approval of the Third A&R 2023 Plan At the Annual Meeting, the Company’s stockholders approved the Third A&R 2023 Plan. The votes on Proposal 2 were as follows: Votes For Votes Against Abstentions Broker Non-Votes 50,659,150 22,888,600 26,748 11,211,890”

Ultragenyx Pharmaceutical Inc. shareholders approved Election of Class I Directors at the 2026-05-14 meeting.

“Proposal No. 1 – Election of Class I Directors At the Annual Meeting, the Company’s stockholders elected the Class I director nominees below to the Company’s Board of Directors to hold office until the 2029 Annual Meeting of Stockholders or until their successors are elected. The votes on Proposal 1 were as follows: Class I Director Nominees Votes For Votes Withheld Broker Non-Votes Emil D. Kakkis, M.D., Ph.D. 72,517,613 1,056,885 11,211,890 Shehnaaz Suliman, M.D. 65,801,638 7,772,860 11,211,890 Daniel G. Welch 66,301,426 7,273,072 11,211,890”

Ultragenyx Pharmaceutical Inc. reported the quarter ended March 31, 2026 results: revenue $136 million. Guidance reaffirmed.

“Higa ir@ultragenyx.com Media Jess Rowlands media@ultragenyx.com Ultragenyx Reports First Quarter 2026 Financial Results and Corporate Update First quarter total revenue of $136 million, Crysvita® revenue of $93 million and Dojolvi® revenue of $18 million Reaffirm 2026 financial guidance, including total revenue of $730 million to $760 million and combined R&D”

Ultragenyx Pharmaceutical Inc. announced a restructuring with charges of approximately $50 million in total restructuring and restructuring-related charges affecting across the Company (10% workforce reduction of approximately 130 employees).

“the Company is implementing a 10% workforce reduction of approximately 130 employees across the Company (the “RIF”). The Company began notifying affected employees on February 12, 2026, and expects this RIF to be substantially completed in the first half of 2026. The Company estimates that it will incur approximately $50 million in total restructuring and restructuring-related charges”

Ultragenyx Pharmaceutical Inc. reported quarter ended March 31, 2024 results: revenue $109 million, net income net loss of $171 million, or $2.03 per share basic and diluted, EPS $2.03 per share basic and diluted. Guidance reaffirmed.

“Pharmaceutical Inc. Investors Joshua Higa ir@ultragenyx.com Ultragenyx Reports First Quarter 2024 Financial Results and Corporate Update First quarter total revenue of $109 million, Crysvita® revenue of $83 million and Dojolvi® revenue of $16 million Reaffirmed 2024 expected total revenue guidance between $500 million to $530 million, Crysvita revenue of”

Ultragenyx Pharmaceutical Inc. updated its the quarter and full year ended December 31, 2023 guidance (reaffirmed).

“On February 15, 2024, Ultragenyx Pharmaceutical Inc. issued a press release announcing its financial results for the three months ended December 31, 2023 and the year ended December 31, 2023”

Ultragenyx Pharmaceutical Inc. reported fiscal year 2024 results: revenue $500 million to $530 million. Guidance initiated.

“2024 expected Total Revenue guidance between $500 million to $530 million”

Ultragenyx Pharmaceutical Inc. reported fiscal year 2023 results: revenue $430 million to $435 million.

“Preliminary 2023 Total Revenue of $430 million to $435 million, Crysvita® Revenue of $ 325 million to $330 million and Dojolvi® revenue of $70 million to $71 million”

Ultragenyx Pharmaceutical Inc. reported the quarter ended September 30, 2023 results: revenue $98.1 million. Guidance reaffirmed.

“Higa ir@ultragenyx.com Media Jeff Blake media@ultragenyx.com Ultragenyx Reports Third Quarter 2023 Financial Results and Corporate Update Third quarter 2023 total revenue of $98.1 million, Crysvita® revenue of $74.9 million and Dojolvi® revenue of $ 16.6 million Reaffirmed 2023 expected total revenue guidance between $425 million to $450 million, Crysvita revenue”

Ultragenyx Pharmaceutical Inc. entered into Underwriting Agreement with J.P. Morgan Securities LLC, Goldman Sachs & Co. LLC, BofA Securities, Inc., and Cowen and Company, LLC (effective 2023-10-18).

“On October 18, 2023, Ultragenyx Pharmaceutical Inc. (“ Ultragenyx ” or the “ Company ”) entered into an underwriting agreement (the “ Underwriting Agreement ”) with J.P. Morgan Securities LLC, Goldman Sachs & Co. LLC, BofA Securities, Inc., and Cowen and Company, LLC (the “ Underwriters ”), providing for the offer and sale in an underwritten public offering (the “ Offering ”) of 8,333,334 shares (the “ Shares ”) of the Company’s common stock, par value $0.001 per share (the “ Common Stock ”), and in lieu of Common Stock to certain investors, pre-funded warrants (the “ Pre-Funded Warrants ”) to purchase 1,666,722 shares of Common Stock (the “ Warrant Shares ”).”

Howard Horn was appointed as Chief Financial Officer and Executive Vice President, Corporate Strategy at Ultragenyx Pharmaceutical Inc..

“Mr. Horn and the Company have modified the effective date of Mr. Horn’s appointment as the Company’s CFO and EVP, Corporate Strategy from October 16, 2023 to October 9, 2023 (the “Effective Date”).”

Ultragenyx Pharmaceutical Inc. reported the quarter ended June 30, 2023 results: revenue $108.3 million, net income net loss of $159.8 million, or $2.25 per share basic and diluted, EPS $2.25 per share basic and diluted. Guidance reaffirmed.

“Mepsevii 8,439 4,933 16,919 9,794 Evkeeza 365 — 577 — Daiichi Sankyo — 1,479 1,479 4,728 Total revenues $ 108,309 $ 89,343 $ 208,805 $ 169,278 Total Revenues Ultragenyx reported $108.3 million in total revenue for the second quarter of 2023, which represents 21% growth compared to the second quarter 2022. This includes second quarter 2023 Crysvita revenue in North”

Howard Horn was appointed as Chief Financial Officer and Executive Vice President, Corporate Strategy at Ultragenyx Pharmaceutical Inc..

“On July 12, 2023, Ultragenyx Pharmaceutical Inc. (the “Company”) announced that Howard Horn has been appointed as the Company’s Chief Financial Officer and Executive Vice President, Corporate Strategy, effective as of October 16, 2023”

Ultragenyx Pharmaceutical Inc. shareholders approved Advisory Vote to Approve Executive Compensation at the 2023-06-07 meeting.

“Proposal No. 5 – Advisory (Non-Binding) Vote to Approve Executive Compensation At the Annual Meeting, the Company’s stockholders voted, on an advisory basis, in favor of a resolution approving the compensation the Company pays to its “named executive officers” as described in the Proxy Statement. The votes on Proposal 5 were as follows: Votes For Votes Against Abstentions Broker Non-Votes 56,684,278 3,204,523 96,625 5,026,508”

Ultragenyx Pharmaceutical Inc. shareholders approved Ratification of Selection of Independent Registered Accounting Firm at the 2023-06-07 meeting.

“Proposal No. 4 – Ratification of Selection of Independent Registered Accounting Firm At the Annual Meeting, the Company’s stockholders ratified the selection of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2023. The votes on Proposal 4 were as follows: Votes For Votes Against Abstentions 63,986,340 934,903 90,691”

Ultragenyx Pharmaceutical Inc. shareholders approved Approval of the A&R ESPP at the 2023-06-07 meeting.

“Proposal No. 3 – Approval of the A&R ESPP At the Annual Meeting, the Company’s stockholders approved the A&R ESPP. The votes on Proposal 3 were as follows: Votes For Votes Against Abstentions Broker Non-Votes 59,717,345 262,515 5,566 5,026,508”

Ultragenyx Pharmaceutical Inc. shareholders approved Approval of the 2023 Plan at the 2023-06-07 meeting.

“Proposal No. 2 – Approval of the 2023 Plan At the Annual Meeting, the Company’s stockholders approved the 2023 Plan. The votes on Proposal 2 were as follows: Votes For Votes Against Abstentions Broker Non-Votes 41,971,776 18,008,590 5,060 5,026,508”

Ultragenyx Pharmaceutical Inc. shareholders approved Election of Class I Directors at the 2023-06-07 meeting.

“Proposal No. 1 – Election of Class I Directors At the Annual Meeting, the Company’s stockholders elected the Class I director nominees below to the Company’s Board of Directors to hold office until the 2026 Annual Meeting of Stockholders or until their successors are elected. The votes on Proposal 1 were as follows: Class I Director Nominees Votes For Votes Withheld Broker Non-Votes Emil D. Kakkis, M.D., Ph.D. 58,836,682 1,148,744 5,026,508 Shehnaaz Suliman, M.D. 55,707,622 4,277,804 5,026,508 Daniel G. Welch 52,266,359 7,719,067 5,026,508”

Ultragenyx Pharmaceutical Inc. reported First Quarter 2023 results: revenue $ 100,496, net income $ (163,972 ), EPS $ (2.33 ). Guidance reaffirmed.

“Selected Financial Data (dollars in thousands, except per share amounts), (unaudited) Three Months Ended March 31, 2023 2022 Total revenues $ 100,496 $ 79,935 Operating expense: Cost of sales 12,257 6,100 Research and development 165,698 143,155 Selling, general and administrative 76,646 67,312 Total operating expense 254,601 216,567 Net loss $ (163,972 ) $ (152,320 ) Net loss per share, basic and diluted $ (2.33 ) $ (2.19 )”

Lars Ekman retired as Director at Ultragenyx Pharmaceutical Inc..

“On March 20, 2023, Lars Ekman, M.D., Ph.D. notified Ultragenyx Pharmaceutical Inc. (the “ Company ”) of his decision to retire from the Board of Directors of the Company (the “ Board ”), effective immediately after the Company’s 2023 Annual Meeting of Stockholders, currently scheduled for June 7, 2023.”

Eric Crombez was appointed as Executive Vice President, Chief Medical Officer at Ultragenyx Pharmaceutical Inc..

“Eric Crombez, M.D., the Company’s current Chief Medical Officer for Gene Therapy and Inborn Errors of Metabolism, will assume the role of Executive Vice President, Chief Medical Officer, effective as of the Effective Date.”

Camille L. Bedrosian changed role as Strategic Development Advisor at Ultragenyx Pharmaceutical Inc..

“On March 14, 2023, Ultragenyx Pharmaceutical Inc. (the “ Company ”) announced that Camille L. Bedrosian, M.D., the Company’s Executive Vice President and Chief Medical Officer, will be transitioning to a new role as Strategic Development Advisor to the Company, effective May 1, 2023”

Ultragenyx Pharmaceutical Inc. reported Full year 2023 results: revenue Crysvita $325 million to $340 million; Dojolvi $65 million to $75 million. Guidance reaffirmed.

“Total revenue in the range of $425 million to $450 million”

Ultragenyx Pharmaceutical Inc. reported three months ended December 31, 2022 and year ended December 31, 2022 results: revenue $103.3 million for Q4 2022; $363.3 million for FY 2022, net income Net loss of $151.8 million for Q4 2022; Net loss of $707.4 million for FY 2022, EPS $(2.16) per share for Q4 2022; $(10.12) per share for FY 2022. Guidance reaffirmed.

“Ultragenyx Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Update”

Ultragenyx Pharmaceutical Inc. reported 2023 results: revenue $425 million to $450 million. Guidance initiated.

“2023 expected Total Product Revenue guidance between $425 million to $450 million”

Ultragenyx Pharmaceutical Inc. reported fiscal year 2022 results: revenue $352 million to $356 million.

“Preliminary 2022 Total Product Revenue of $352 million to $356 million”

Mardi Dier resigned as Executive Vice President and Chief Financial Officer at Ultragenyx Pharmaceutical Inc..

“On November 10, 2022, Ultragenyx Pharmaceutical Inc. (the “ Company ”) announced that Mardi Dier had informed the Company of her decision to voluntarily resign from her position as the Company’s Executive Vice President and Chief Financial Officer, effective as of November 15, 2022, to pursue another opportunity.”

Ultragenyx Pharmaceutical Inc. reported the quarter ended September 30, 2022 results: revenue $90.7 million, net income $245.1 million, EPS $3.50 per share basic and diluted. Guidance reaffirmed.

“Third Quarter 2022 Financial Results Net Revenues For the third quarter of 2022, Ultragenyx reported $ 90.7 million in total revenue. Ultragenyx recognized $64.5 million in Crysvita (burosumab) revenue in the Ultragenyx territories, which includes $ 51.3 million in collaboration revenue in the North American profit share territory and net product sales in other regions of $ 13.2 million. Total royalty revenue related to European Crysvita sales was $5.4 million. Dojolvi (triheptanoin) product sales in the third quarter of 2022 were $13.3 million. Mepsevii (vestronidase alfa) product sales for the third quarter of 2022 were $6.0 million. Total revenue for the third quarter of 2022 also includes $1.5 million related to technical assistance following the successful completion of technology transfer activities with Daiichi Sankyo. This compares to total revenue in the third quarter of 2021, which includes $12.1 million related to the technology transfer services which were ongoing at the ti”

Amrit Ray was appointed as Class III director at Ultragenyx Pharmaceutical Inc..

“the Board appointed Amrit Ray, M.D. as a Class III director of the Board effective April 19, 2022”

William Aliski departed as director at Ultragenyx Pharmaceutical Inc..

“William Aliski notified Ultragenyx Pharmaceutical Inc. (the “ Company ”) that he will not stand for re-election as a member of the Board of Directors”